Abstract
The pharmacokinetic characteristics of levetiracetam are described, and the interaction effects of concomitant antiseizure medications on levetiracetam in terms of its pharmacokinetics and pharmacodynamics are highlighted.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moseley BD, Otoul C, Staelens L, Stockis A. Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: pooled analysis of data from randomized clinical trials. Epilepsy Res. 2019;158:106218.
Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55:57–66.
Gaston TE, Bekib EM, Cutter GR, Liu Y, Szaflarski JP, UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586–92.
Aldaz A, Alzueta N, Viteri C. Influence of comedication on levetiracetam pharmacokinetics. Ther Drug Monit. 2018;40:130–4.
Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 2002;48:217–9.
Summary of product characteristics: Cenobamate (XCopri). SK Life Science Inc. Last update Aug 2020.
Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–24.
Falcao A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P. Pharmacokinetics, drug interactions and exposure-response relationships of eslicarbazepine acetate in adult patients with partialonset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis. CNS Drugs. 2012;26:79–91.
Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CB, Shields WD. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia. 2002;43:518–24.
Toutopoulou M, Weshke B, Kaindl AM. Lacsamide lowers valproate and levetiracetam levels. Neuropediatrics. 2017;48:188–9.
May TW, Rambeck B, Jurgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit. 2003;25:690–9.
Majid O, Laurenza A, Ferry J, Hussein Z. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset: pooled analysis of clinical trials. Br J Clin Pharmacol. 2016;82:422–30.
Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013;54:1490–7.
Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77–85.
Summary of product characteristics: Stiripentol (Diacomit). Alan Pharmceuticals. Last update 20 Sept 2018.
Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev Contemp Pharmacother. 2004;13:1–168.
Coupez R, Nicolas JM, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia. 2003;44:171–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Patsalos, P.N. (2022). Levetiracetam. In: Antiseizure Medication Interactions. Springer, Cham. https://doi.org/10.1007/978-3-030-82790-8_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-82790-8_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-82789-2
Online ISBN: 978-3-030-82790-8
eBook Packages: MedicineMedicine (R0)